Your browser doesn't support javascript.
loading
Dopamine genetic risk score predicts impulse control behaviors in Parkinson's disease.
Hall, Alison; Weaver, Samuel R; Compton, Lindsey J; Byblow, Winston D; Jenkinson, Ned; MacDonald, Hayley J.
Afiliación
  • Hall A; School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK.
  • Weaver SR; Centre for Human Brain Health, University of Birmingham, Birmingham, UK.
  • Compton LJ; School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK.
  • Byblow WD; Centre for Human Brain Health, University of Birmingham, Birmingham, UK.
  • Jenkinson N; School of Biosciences, University of Birmingham, Birmingham, UK.
  • MacDonald HJ; Department of Exercise Sciences, University of Auckland, Auckland, New Zealand.
Clin Park Relat Disord ; 5: 100113, 2021.
Article en En | MEDLINE | ID: mdl-34765965
INTRODUCTION: Up to 40% of Parkinson's disease patients taking dopamine agonist medication develop impulse control behaviors which can have severe negative consequences. The current study aimed to utilize dopamine genetics to identify patients most at risk of developing these behaviors. METHODS: Demographic, clinical, and genetic data were obtained from the Parkinson's Progression Markers Initiative for de novo patients (n = 327), patients taking dopamine agonists (n = 146), and healthy controls (n = 160). Impulsive behaviors were identified using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease. A dopamine genetic risk score was calculated for each patient according to polymorphisms in genes coding for dopamine D1, D2 and D3 receptors, and catechol-O-methyltransferase. A higher score reflected higher central dopamine neurotransmission. RESULTS: Patients on agonists with a low dopamine genetic risk score were over 18 times more likely to have an impulsive behavior compared to higher scores (p = 0.04). The 38% of patients taking agonists who had at least one impulsive behavior were more likely to be male and report higher Unified Parkinson's Disease Rating Scale I&II scores. With increasing time on dopamine agonists (range 92-2283 days, mean 798 ± 565 standard deviation), only patients with a high dopamine genetic risk score showed an increase in number of impulsive behaviors (p = 0.033). Predictive effects of the gene score were not present in de novo or healthy control. CONCLUSIONS: A dopamine genetic risk score can identify patients most at risk of developing impulsive behaviors on dopamine agonist medication and predict how these behaviors may worsen over time.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Clin Park Relat Disord Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Clin Park Relat Disord Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido